Intragastric balloon (IGB) is a modern interventional minimally invasive treatment of obesity. The aim of this study was to assess the effectiveness and safety of IGB among obese patients. Sixty-one patients with baseline mean weight of 105.93 (±20.36) kg and body mass index (BMI) of 37.80 (±5.60) kg/m2 completed a 1-year follow-up after placement of IGB for weight reduction. Demographic characteristics with clinical data were collected. IGB was placed under sedation and followed-up for a period of 1 year. Successful weight reduction was defined as participant achieving absolute weight reduction of more than 10%. The mean age of patients was 34.87 (±10.77) years, and 64.71% of the patients were female. Vomiting and abdominal pain were the most reported minor complications. Weight and BMI were significantly reduced, 1 year later, to 92.93 (±20.89) kg and 33.07 (±5.77) kg/m2 , respectively. This yields an average of 12.49 (±8.31) kg reduction of the original weight. Furthermore, 54.1%, 72.1%, and 78.7% of participants achieved more than 10%, 7.5%, and 5% weight reduction, respectively. Obese patients with initial gastritis and those who developed abdominal pain achieved higher weight reduction. IGB is a safe and effective procedure to achieve target weight reduction in a short period. Ensuring sustainability of weight reduction requires longer duration of follow-up.
Key words: Intragastric balloon, obesity, weight loss, body mass index
|
